Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational Study to Evaluate the Real-world Experience of Patients Who Are Initiating Treatment With Telotristat Ethyl (XERMELO)

Next Previous
X
Search
Trial Profile

An Observational Study to Evaluate the Real-world Experience of Patients Who Are Initiating Treatment With Telotristat Ethyl (XERMELO)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telotristat etiprate (Primary)
  • Indications Malignant carcinoid syndrome
  • Focus Therapeutic Use
  • Acronyms RELAX
  • Sponsors Lexicon Pharmaceuticals; TerSera Therapeutics

    • Most Recent Events

    • 18 Jan 2022 Status changed from active, no longer recruiting to completed.
    • 09 Nov 2021 Results published in the TerSera Therapeutics Media Release
    • 09 Nov 2021 According to a TerSera Therapeutics media release, The data were presented in virtual poster sessions during the North American Neuroendocrine Tumor Society's (NANETS) Multidisciplinary NET Medical Symposium on November 3-6, 2021.1

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top